ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1464 • ACR Convergence 2022

    Patients with Late-onset-Systemic Lupus Erythematosus Have Different Disease Presentations

    Ganiat Adeogun, Alex Camai, Sarah Green and April Barnado, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Systemic lupus erythematosus (SLE) predominantly affects females of reproductive age but can affect patients later in life. Late-onset (LO)-SLE is defined as SLE diagnosed…
  • Abstract Number: 1449 • ACR Convergence 2022

    Incidence and Risk Factors for Active Tuberculosis in Patients with Systemic Lupus Erythematosus: A Multicenter Prospective Cohort Study

    Lifan Zhang1, xiaoqing zou2, Lantian Xie3, Jianghao Liu3, zhengrong yang4, qifei cao4, Chunlei Li5, Xiaochuan Sun5, Fengchun ZHANG6, Yan Zhao7, Xiaofeng Zeng8 and Xiaoqing Liu1, 1Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Clinical Epidemiology Unit, Peking Union Medical College, International Clinical Epidemiology Network; Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 2Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 3Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China, 4Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 5Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 6Peking Union Medical College Hospital, Beijing, China, 7Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, 8Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China

    Background/Purpose: The burden of tuberculosis (TB) and systemic lupus erythematosus (SLE) in China are both the second largest in the world. Patients with SLE are…
  • Abstract Number: 1463 • ACR Convergence 2022

    Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria

    Shudan Wang1, Allan Spielman2, Mindy Ginsberg2, Michelle Petri3, Brad Rovin4, Jill Buyon5 and Anna Broder6, 1Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, 2Albert Einstein College of Medicine, Bronx, NY, 3Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 4The Ohio State University, Columbus, OH, 5NYU Grossman School of Medicine, New York, NY, 6Hackensack University Medical Center, Hackensack, NJ

    Background/Purpose: Lupus nephritis remains a common cause of morbidity and mortality in systemic lupus erythematosus (SLE). Current guidelines recommend performing a kidney biopsy at urine…
  • Abstract Number: 1462 • ACR Convergence 2022

    Exploring the Potential of Urine: Serum Fractional Excretion Ratios as Disease Biomarkers in Active Lupus Nephritis

    Samar Soliman1, Samantha Stanley2, Kamala Vanarsa2, Faten Ismail3, Chi Chiu Mok4 and Chandra mohan5, 1Rheumatology Department, Faculty of Medicine, Minia university, Minya, Egypt, 2Department of Biomedical Engineering, University of Houston, Houston, TX, 3Department of Rheumatology, Faculty of Medicine, Minia University, Minia, Egypt, 4Tuen Mun Hospital, Hong Kong, China, 5University of Houston, Houston, TX

    Background/Purpose: The goal of this exploratory study is to determine if urine:serum fractional excretion ratios can outperform the corresponding urinary biomarker proteins in identifying active…
  • Abstract Number: 1458 • ACR Convergence 2022

    Systemic Lupus Erythematosus (SLE) Patients with Cognitive Impairment Experience More Fatigue Compared to Patients Without Impairment

    Delansie Lawrence1, Jiandong Su1, Andrea Knight2, Kathleen Bingham3, Mahta Kakvan1, Maria Carmela Tartaglia4, Leslet Ruttan5, Joan Wither6, May Choi7, Simone Appenzeller8, Nicole Anderson1, Dennisse Bonilla1, Patricia Katz9, Dorcas Beaton10, Robin Green5, Zahi Touma1 and Michelle Barraclough11, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 2The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 3Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, 4University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, 5University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, 6Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, 7Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, 8Unicamp, Campinas, São Paulo, Brazil, 9UCSF, San Rafael, CA, 10Institute for Work & Health, Toronto, ON, Canada, 11Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada

    Background/Purpose: Cognitive impairment (CI) is highly prevalent in patients with systemic lupus erythematosus (SLE). Objective prevalence rates are reported as 38% [range: 20% to 80%]…
  • Abstract Number: 1408 • ACR Convergence 2022

    In RA Patients Without Prevalent CVD, Incident CVD Is Only Associated with Traditional Risk Factors: A 20-year Follow up in the CARRÉ Cohort Study

    Reinder Raadsen1, Rabia Agca2, Maarten Boers3, Vokko van Halm2, Mike Peters4, Yvo Smulders2, Joline Beulens2, Marieke Blom2, Coen Stehouwer5, Alexandre Voskuyl2, Willem Lems6 and Michael Nurmohamed7, 1Reade Rheumatology Center, Amsterdam, Netherlands, 2Amsterdam UMC, Amsterdam, Netherlands, 3Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 4Amsterdam UMC; UMC Utrecht, Amsterdam, Netherlands, 5MUmc, Amsterdam, Netherlands, 6Amsterdam University Medical Centers, Amsterdam, Netherlands, 7Amsterdam University Medical Center, Kortenhoef, Netherlands

    Background/Purpose: We have documented that patients with rheumatoid arthritis (RA) are at increased risk to develop cardiovascular disease (CVD) compared to the general population, even…
  • Abstract Number: 1441 • ACR Convergence 2022

    Prevalence of Secondary Connective Tissue Diseases and Autoantibodies Among Racial and Ethnic Groups in Systemic Lupus Erythematosus Patients in the Manhattan Lupus Surveillance Program

    Brendan Denvir1, Philip Carlucci2, Jill Buyon3, H Michael Belmont4, Kelly Corbitt1, Sara Sahl5, Jane Salmon6, Anca Askanase7, Joan Bathon7, Laura Geraldino-Pardilla8, Yousaf Ali9, Ellen M. Ginzler10, Chaim Putterman11, Caroline Gordon12, Hilary Parton13 and Peter Izmirly3, 1New York University, New York, NY, 2New York University School of Medicine, New York, NY, 3NYU Grossman School of Medicine, New York, NY, 4NYU School of Medicine, New York, NY, 5Harbor-University of California Medical Center, Los Angeles, CA, 6Hospital for Special Surgery, New York, NY, 7Columbia University Medical Center, New York, NY, 8Columbia University, New York, NY, 9Icahn School of Medicine at Mount Sinai, New York, NY, 10SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, 11Albert Einstein College of Medicine, Bronx, NY, 12Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 13New York City Department of Health and Mental Hygiene, New York, NY

    Background/Purpose: Epidemiologic data of secondary connective tissue disease and autoantibody profiles among patients with systemic lupus erythematosus (SLE) remains limited for racial/ethnic populations in the…
  • Abstract Number: 1454 • ACR Convergence 2022

    A High Genetic Risk of SLE Is Associated with an Increased Risk of Myocardial Infarction; A Combined Observational and Mendelian Randomization Study

    Sarah Reid1, Johanna K Sandling1, Pascal Pucholt1, Ahmed Sayadi1, Christopher Sjöwall2, Karoline Lerang3, Andreas Jönsen4, Anders A Bengtsson4, Øyvind Molberg3, Anna Rudin5, Solbritt Rantapää-Dahlqvist6, Lars Ronnblom7 and Dag Leonard1, 1Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 2Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden, 3Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 4Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, 5Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, 6Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, 7Uppsala University, Uppsala, Sweden

    Background/Purpose: The reasons for the high cardiovascular morbidity in patients with SLE are not fully understood. Here, we combine a mendelian randomization (MR) approach and…
  • Abstract Number: 1356 • ACR Convergence 2022

    Patient-perceived Disease Burden and Self-reported Medication Adherence in Systemic Autoimmune Diseases: A Monocentric Observational Study

    Camille Mettler1, Veronique Le Guern2, Paul Legendre1, Caroline Morbieu1, Tali-Anne Swebel1, Xavier Puéchal3, Pascal Cohen3, Hicham Kardaoui1, Alexandre Moores1, Luc Mouthon3, Nathalie Costedoat-Chalumeau4 and Benjamin Terrier3, 1Department of Internal Medicine, National Referral Center for Rare Systemic and Autoimmune Diseases, Cochin Hospital, Paris, France, 2Hôpital Cochin, Paris, France, 3National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 4Inserm DR Paris 5, Paris, France

    Background/Purpose: Systemic autoimmune diseases (AID) are chronic conditions with significant burden related to the disease itself, its management, and treatments. Burden refers to the workload…
  • Abstract Number: 1417 • ACR Convergence 2022

    Clinical and Demographic Characteristics of Patients with RF+/ACPA+ RA and First-Line TNF Inhibitor versus Abatacept Treatment Choice in Real-World Clinical Practice

    Gordon Lam1, Hanke Zheng2, Emily Bland3, Vardhaman Patel4, Laetitia N’Dri5, Parisa Asgarisabet3, Keith Wittstock4, Cherrishe Brown-Bickerstaff3, Mark Chaballa2, Bruce Feinberg3, Vadim Khaychuk6 and Andrew J Klink3, 1Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, 2Bristol Myers Squibb, Princeton, NJ, 3Cardinal Health, Dublin, OH, 4Bristol Myers Squibb, Lawrence Township, NJ, 5Bristol Myers Squibb, Princeton, 6Bristol Myers Squibb, Pennington, MA

    Background/Purpose: Early intensive treatment (tx) is an accepted paradigm in the tx of patients (pts) with RA with poor prognostic factors (eg, RF/ACPA seropositivity); however,…
  • Abstract Number: 1465 • ACR Convergence 2022

    Clinical Profiling and Antiphospholipid Antibody (aPL) Associations in Indian Systemic Lupus Erythematosus (SLE) Cohort

    Vineeta Shobha1, Liza Rajasekhar2, Sandra Manuel1, Chengappa Kavadichanda3, Ashish J Mathew4, Ranjan Gupta5, Manish Rathi6, Parasar Ghosh7, Saumya Ranjan Tripathy8, Avinash Jain9 and Amita Aggarwal10, 1St. John’s Medical College Hospital, Bangalore, India, 2Nizam's Institute of Medical Sciences, Madhapur, India, 3JIPMER, Pondicherry, Puducherry, India, 4Rigshospitalet, Copenhagen, Denmark, 5All India Institute of Medical Sciences, New Delhi, India, 6PGIMER Chandigarh, Chandigarh, India, 7Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, 8SCB medical college, Cuttack, India, 9SMS Medical College, Lucknow, India, 10Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Background/Purpose: Antiphospholipid Antibody (aPL) are described in 11-40% of patients with SLE. Whether the presence of any of the aPLs or combinations thereof, can accurately…
  • Abstract Number: 1450 • ACR Convergence 2022

    Impact of Time to Remission, Flares and Time on Immunosuppressives on the Estimated Glomerular Filtration Rate in Lupus Nephritis

    KONSTANTINOS TSELIOS1, Dafna Gladman2, Jiandong Su3 and Murray Urowitz4, 1McMaster University, Population Health Research Institute, Hamilton, ON, Canada, 2Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 3Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 4University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada

    Background/Purpose: Time to complete remission, subsequent flares and time on immunosuppressives after complete remission are major determinants of the progression to advanced chronic kidney disease…
  • Abstract Number: 1345 • ACR Convergence 2022

    Is Perceived Stress Associated with COVID-19 or Having a Systemic Rheumatic Disease?

    Jonah Levine, Medha Barbhaiya, Vivian Bykerk, Deanna Jannat-Khah, DrPH, MSPH and Lisa Mandl, Hospital for Special Surgery, New York, NY

    Background/Purpose: The SARS-CoV-2 pandemic is a worldwide mental health crisis. We evaluated perceived stress in patients seeking care for musculoskeletal conditions, and explored associations with…
  • Abstract Number: 1461 • ACR Convergence 2022

    The Frequency of Systemic Lupus Erythematosus in Patients with Immune Thrombocytopenic Purpura: A Systematic Meta-analysis

    Omer Pamuk1 and Sarfaraz Hasni2, 1NIH/NIAMS, Bethesda, MD, 2NIAMS/NIH, Bethesda, MD

    Background/Purpose: Immune thrombocytopenic purpura (ITP) is an organ-specific autoimmune disease and its etiopathogenetic mechanisms are suggestive of systemic autoimmune diseases (SAD) such as systemic lupus…
  • Abstract Number: 1428 • ACR Convergence 2022

    Molecular and Clinical Profiling of Rheumatoid Arthritis Patients Predicts the Response to Rituximab

    Daniel Toro-Domínguez1, José Linares-Blanco1, Raúl López-Domínguez2, Pilar S. López-Garrido2, Georgina Galicia-Rosas1, Pedro Carmona-Sáez2 and Marta Alarcon-Riquelme1, 1Center for Genomics and Oncological Research (GENYO), Granada, Spain, 2University of Granada, Granada, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is one of the most prevalent rheumatic diseases, mainly characterized by chronically painful, swollen joints that can severely impair physical function…
  • « Previous Page
  • 1
  • …
  • 380
  • 381
  • 382
  • 383
  • 384
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology